Asymmetry Capital Management’s Cytokinetics CYTK Stock Holding History

Asymmetry Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$10.3M	Sell	225,032 -21,304	-9%	-$822K	5.45%	8
2021 Q3	$8.8M	Buy	+246,336	New	+$7.25M	5.29%	8
2020 Q4	–	Sell	-340,253	Closed	-$7.37M	–	36
2020 Q3	$7.37M	Buy	340,253 +134,167	+65%	+$3.14M	4.73%	6
2020 Q2	$4.86M	Buy	206,086 +1,835	+0.9%	+$34.4K	3.72%	10
2020 Q1	$2.41M	Buy	204,251 +119,079	+140%	+$1.52M	2.63%	15
2019 Q4	$904K	Buy	+85,172	New	+$875K	1.62%	29

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Asymmetry Capital Management's CYTK Position: Q4 2021 in Review

Asymmetry Capital Management reduced its Cytokinetics (CYTK) stake by 8.6% in Q4 2021, selling an estimated $822K and leaving 225,032 shares worth $10.3M. The position accounts for 5.45% of the portfolio, ranked #8.

Asymmetry Capital Management first reported a position in CYTK in Q4 2019 and has held it in 6 quarters since. 250 funds tracked by Wall St. Rank hold CYTK as of Q4 2021.

Asymmetry Capital Management held 225,032 shares of Cytokinetics worth $10.3M as of Q4 2021.
Asymmetry Capital Management sold 21,304 Cytokinetics shares in Q4 2021, an estimated $822K.
Cytokinetics made up 5.45% of Asymmetry Capital Management's portfolio in Q4 2021, its #8 holding.
Asymmetry Capital Management first reported a position in Cytokinetics in Q4 2019 and has held it in 6 quarters since.
250 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2021.

Based on Asymmetry Capital Management's 13F filing for Q4 2021, filed 19 Jan 2022.